2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Recurrence
2
Lymphoma
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 2a
1
Metastatic Solid Tumors
1
Malignant Solid Tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Lethal Congenital Contracture Syndrome 2
1
Hematologic Neoplasms
1
Gynecological Solid Tumors
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Tumor Malignancies
1
Interventions
Carboplatin
784
Pemetrexed
607
Cisplatin
545
Paclitaxel
491
pembrolizumab
464
Docetaxel
440
Gemcitabine
328
Erlotinib Hydrochloride
307
Radiotherapy
258
Nivolumab
244
Bevacizumab
233
osimertinib
178
Drug Therapy
164
durvalumab
157
atezolizumab
135
Gefitinib
134
Radiosurgery
133
Vinorelbine
111
Cetuximab
97
130-nm albumin-bound paclitaxel
94
Ipilimumab
86
Magnetic Resonance Spectroscopy
84
Taxes
79
Surgical Procedures, Operative
74
Afatinib
68
Albumin-Bound Paclitaxel
66
Specimen Handling
61
Etoposide
61
Cyclophosphamide
60
tislelizumab
59
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Antibodies, Bispecific
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled